{"nctId":"NCT03083665","briefTitle":"A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy","startDateStruct":{"date":"2017-08-22","type":"ACTUAL"},"conditions":["Partial Seizures With or Without Secondary Generalization","Epilepsy"],"count":449,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"BRV 50 mg/day","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo","Drug: Brivaracetam"]},{"label":"BRV 200 mg/day","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo","Drug: Brivaracetam"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Brivaracetam","otherNames":["Briviact"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects (male or female) from 16 to 80 years of age at Visit 1, both inclusive\n* Female subjects with childbearing potential are eligible if they use a medically accepted contraceptive method\n* Subjects having at least 8 partial seizures (according to the 1981 ILAE classification) during the 8-Week Baseline Period with at least 2 partial seizures during each 4-week interval of the Baseline Period\n* Subjects having at least 2 partial seizures whether or not secondary generalization per month during the 3 months preceding Visit 1\n* Subjects uncontrolled while treated by 1 or 2 permitted concomitant antiepileptic drug \\[AED\\](s). Vagal Nerve Stimulation (VNS) is allowed and will be counted as a concomitant AED\n\nExclusion Criteria:\n\n* Subject has history or presence of status epilepticus during the year preceding Visit 1 or during Baseline\n* Subject is currently treated with levetiracetam\n* Subject has taken levetiracetam within 90 days prior to Visit 1","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"80 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)","description":"An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. Treatment-Emergent AEs were defined as AEs which had onset on or after the first dose of IMP. As per planned analysis, safety data for all study periods was combined excluding Open-Label Temporary period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.4","spread":null},{"groupId":"OG001","value":"57.0","spread":null},{"groupId":"OG002","value":"60.1","spread":null},{"groupId":"OG003","value":"26.6","spread":null},{"groupId":"OG004","value":"19.1","spread":null},{"groupId":"OG005","value":"23.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Treatment-Emergent AEs (TEAEs) Leading to Study Withdrawal","description":"An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. Treatment-Emergent AEs were defined as AEs which had onset on or after the first dose of IMP. As per planned analysis, safety data for all study periods was combined excluding Open-Label Temporary period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null},{"groupId":"OG001","value":"2.6","spread":null},{"groupId":"OG002","value":"3.4","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)","description":"Serious Adverse event (SAE) was defined as any events which: • results in death, • is life-threatening threatening (note that this did not include a reaction that might have caused death had it occurred in a more severe form.), •results in significant or persistent disability/incapacity, • results in a congenital anomaly/birth defect (including that occurring in a fetus), • results in Important medical event that, based upon appropriate medical judgment, may jeopardize the participant and might require medical or surgical intervention to prevent 1 of the other outcomes listed here, and • results in initial inpatient hospitalization or prolongation of hospitalization. As per planned analysis, safety data for all study periods was combined excluding Open-Label Temporary period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null},{"groupId":"OG001","value":"1.3","spread":null},{"groupId":"OG002","value":"2.7","spread":null},{"groupId":"OG003","value":"4.7","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"2.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Partial Seizure Frequency Per 28 Days During the 12-week Treatment Period","description":"According to International League Against Epilepsy (ILAE) classification (1981), seizures were classified as type IA (IA1, IA2, IA3, and IA4), IB, IC, II (IIA, IIB, IIC, IID, IIE, and IIF) or III. 28 day adjusted seizure frequency for partial seizures (seizure types IA+IB+IC) was calculated for treatment period by dividing the number of partial seizures by the number of days for which the DRC was completed for treatment period and multiplying the resulting value by 28.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.17","spread":null},{"groupId":"OG001","value":"5.93","spread":null},{"groupId":"OG002","value":"4.19","spread":null}]}]}]},{"type":"SECONDARY","title":"50% Responder Rate Based on Percent Change in Partial Seizure Frequency Per 28 Days From Baseline to the 12-week Treatment Period","description":"Responders were those participants with at least 50% reduction from Baseline to the 12-week Treatment Period in partial seizure frequency per 28 days. 50% Responder rate was calculated for treatment period by dividing the number of 50% responders by the number of participants in the analysis set and multiplying the resulting value by 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.0","spread":null},{"groupId":"OG001","value":"41.1","spread":null},{"groupId":"OG002","value":"49.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Partial Seizure Frequency Per 28 Days From Baseline to the 12-week Treatment Period","description":"Percent change from Baseline to the Treatment Period in partial seizure frequency was calculated by subtracting 28-day adjusted Treatment Period partial seizure frequency from 28-day adjusted Baseline Period partial seizure frequency, and multiplying the resulting quantity by 100 and dividing by the Baseline Period 28-day adjusted partial seizure frequency. A negative value in percent change from Baseline indicates a decrease in partial seizure frequency from Baseline to the Treatment Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.3","spread":null},{"groupId":"OG001","value":"38.9","spread":null},{"groupId":"OG002","value":"46.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Categorized Percent Change in Partial Seizure Frequency Per 28 Days From Baseline to the 12-week Treatment Period","description":"The percentage of participants within each of the following categories of percent change in partial seizure frequency from Baseline to the Treatment Period were summarized for each treatment group: 100%, 75% to less than 100%, 50% to less than 75%, 25% to less than 50%, -25% to less than 25%, and less than -25%. Percent change from Baseline to the Treatment Period in partial seizure frequency was calculated by subtracting 28-day adjusted Treatment Period partial seizure frequency from 28-day adjusted Baseline Period partial seizure frequency and multiplying the resulting quantity by 100 and dividing by the Baseline Period 28-day adjusted partial seizure frequency.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"5.3","spread":null},{"groupId":"OG002","value":"7.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"14.6","spread":null},{"groupId":"OG002","value":"17.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":null},{"groupId":"OG001","value":"21.2","spread":null},{"groupId":"OG002","value":"24.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.2","spread":null},{"groupId":"OG001","value":"16.6","spread":null},{"groupId":"OG002","value":"20.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null},{"groupId":"OG001","value":"31.1","spread":null},{"groupId":"OG002","value":"18.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":null},{"groupId":"OG001","value":"11.3","spread":null},{"groupId":"OG002","value":"11.5","spread":null}]}]}]},{"type":"SECONDARY","title":"All Seizure Frequency (Partial, Generalized, and Unclassified Epileptic Seizures) Per 28 Days During the 12-week Treatment Period","description":"There were three types of epileptic seizures: Partial epileptic seizures (Type I), Generalized epileptic seizures (Type II) and unclassified epileptic seizures (Type III). 28 day adjusted seizure frequency for all seizure types was calculated for treatment period by dividing the number of targeted seizures by the number of days for which the DRC was completed for treatment period and multiplying the resulting value by 28.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.17","spread":null},{"groupId":"OG001","value":"5.93","spread":null},{"groupId":"OG002","value":"4.19","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Are Seizure Free (Partial, All Epileptic Seizures) During the 12-week Treatment Period","description":"Participants were defined as seizure free, if they did not have missing diary days and no reported seizures during the Treatment Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4.6","spread":null},{"groupId":"OG002","value":"6.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4.6","spread":null},{"groupId":"OG002","value":"6.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to 1st Partial Seizure During the 12-week Treatment Period","description":"The evaluation of time to 1st partial seizure was based on the relative day of occurrence of the 1st partial seizure during the Treatment Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to 5th Partial Seizure During the 12-week Treatment Period","description":"The evaluation of time to 5th partial seizure was based on the relative day of occurrence of the 5th partial seizure during the Treatment Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to 10th Partial Seizure During the 12-week Treatment Period","description":"The evaluation of time to 10th partial seizure was based on the relative day of occurrence of the 10th partial seizure during the Treatment Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"59","spread":null},{"groupId":"OG002","value":"69","spread":null}]}]}]},{"type":"SECONDARY","title":"Brivaracetam Plasma Concentration","description":"Blood samples were collected at indicated time points for the 50mg/day and 200mg/day groups to determine the brivaracetam plasma concentration. Participants of arm 'BRV 200 mg/day' received BRV 200 mg/day until Week 12 only and 150 mg/day during the Transition Period at Week 14. Therefore, the data is reported according to the dosage information at specified time point. As per planned analysis, one blood sample was collected for BRV plasma levels during each dosing interval between 0 to 4 hours, 4 to 8 hours, and 8 to 12 hours postdose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.68556","spread":"95.6"},{"groupId":"OG001","value":"3.4340","spread":"42.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.66523","spread":"38.6"},{"groupId":"OG001","value":"2.0615","spread":"334.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18427","spread":"979.4"},{"groupId":"OG001","value":"1.2144","spread":"100.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.75902","spread":"88.8"},{"groupId":"OG001","value":"3.0038","spread":"120.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.64781","spread":"39.2"},{"groupId":"OG001","value":"2.8516","spread":"43.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.39652","spread":"54.7"},{"groupId":"OG001","value":"1.1054","spread":"74.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.76942","spread":"87.3"},{"groupId":"OG001","value":"2.9983","spread":"127.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.76172","spread":"34.0"},{"groupId":"OG001","value":"2.7030","spread":"54.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27840","spread":"10.9"},{"groupId":"OG001","value":"1.5590","spread":"67.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.77400","spread":"89.5"},{"groupId":"OG001","value":"3.2508","spread":"121.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65274","spread":"39.4"},{"groupId":"OG001","value":"1.6017","spread":"838.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18229","spread":"579.5"},{"groupId":"OG001","value":"1.5001","spread":"45.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.75949","spread":"85.3"},{"groupId":"OG002","value":"2.4989","spread":"54.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.75692","spread":"34.6"},{"groupId":"OG002","value":"1.4383","spread":"309.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.41286","spread":"66.4"},{"groupId":"OG002","value":"0.82681","spread":"30.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":149},"commonTop":["Somnolence","Dizziness","Nasopharyngitis","Headache","Upper respiratory tract infection"]}}}